Significance of E-Cadherin and p16 Advanced Endometrial Cancer: A Gynecologic Oncology Group Phase II Study

被引：0
|
作者：
Singh, M.
Darcy, K. M.
Brady, W. E.
Weber, Z.
Akalin, A.
Whitney, C. W.
Zaino, R.
Ramirez, N.
Leslie, K. K.
机构：
[1] SUNY Stony Brook, Stony Brook, NY 11794 USA
[2] New York State Dept Hlth, Roswell Pk Mem Inst, Gynecol Oncol Grp, Buffalo, NY 14263 USA
[3] Univ Colorado Denver, Aurora, CO USA
[4] Univ Massachusetts, Worcester, MA 01605 USA
[5] Christiana Gynecol Grp, Newark, DE USA
[6] Hershey Med Ctr, Hershey, PA USA
[7] Nationwide Childrens Hosp, Columbus, OH USA
[8] Univ Iowa, Iowa City, IA USA
来源：
LABORATORY INVESTIGATION | 2010年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1180
引用
收藏
页码：263A / 264A
页数：2
相关论文
共 50 条
  • [21] Phase II Trial of Ixabepilone As Second-Line Treatment in Advanced Endometrial Cancer: Gynecologic Oncology Group Trial 129-P
    Dizon, Don S.
    Blessing, John A.
    McMeekin, D. Scott
    Sharma, Sudarshan K.
    DiSilvestro, Paul
    Alvarez, Ronald D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) : 3104 - 3108
  • [22] Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: A Gynecologic Oncology Group Study
    Covens, Allan L.
    Filiaci, Virginia
    Gersell, Deborah
    Lutman, Christopher V.
    Bonebrake, Albert
    Lee, Yi-Chun
    GYNECOLOGIC ONCOLOGY, 2011, 120 (02) : 185 - 188
  • [23] HPV ACTING ON E-CADHERIN, P53 AND P16: LITERATURE REVIEW
    Ottria, L.
    Candotto, V.
    Cura, F.
    Baggi, L.
    Arcuri, C.
    Nardone, M.
    Gaudio, R. M.
    Gatto, R.
    Spadari, F.
    Carinci, F.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2018, 32 (02): : 73 - 79
  • [24] Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study
    Fiorica, JV
    Brunetto, VL
    Hanjani, P
    Lentz, SS
    Mannel, R
    Andersen, W
    GYNECOLOGIC ONCOLOGY, 2004, 92 (01) : 10 - 14
  • [25] PHASE-II TRIAL OF ETOPOSIDE IN THE MANAGEMENT OF ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
    SLAYTON, RE
    BLESSING, JA
    DELGADO, G
    CANCER TREATMENT REPORTS, 1982, 66 (08): : 1669 - 1671
  • [26] A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group (GOG) Study
    Aghajanian, C.
    Sill, M. W.
    Darcy, K.
    Greer, B.
    McMeekin, D. S.
    Rose, P. G.
    Rotmensch, J.
    Barnes, M. N.
    Hanjani, P.
    Leslie, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] PHASE-II TRIAL OF PIPERAZINEDIONE IN THE TREATMENT OF ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA - A GYNECOLOGIC-ONCOLOGY-GROUP STUDY
    THIGPEN, JT
    BLESSING, JA
    HOMESLEY, HD
    PETTY, W
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1986, 9 (01): : 21 - 23
  • [28] PHASE-II TRIAL OF ADRIAMYCIN IN THE TREATMENT OF ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA - GYNECOLOGIC ONCOLOGY GROUP-STUDY
    THIGPEN, JT
    BUCHSBAUM, HJ
    MANGAN, C
    BLESSING, JA
    CANCER TREATMENT REPORTS, 1979, 63 (01): : 21 - 27
  • [29] Methylation of DAPK, P16 and E-Cadherin gene in liver cancer tissues and protein expression level
    Tang, Hongmei
    Yao, Xingguo
    Li, Chunlian
    Liu, Pingping
    Ma, Bingqi
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (03): : 3787 - 3792
  • [30] Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: A Phase II study of the Gynecologic Oncology Group
    Moore, DH
    Blessing, JA
    Dunton, C
    Buller, RE
    Reid, GC
    GYNECOLOGIC ONCOLOGY, 1999, 75 (03) : 473 - 475
12345